2002
DOI: 10.1016/s0304-3940(02)00332-4
|View full text |Cite
|
Sign up to set email alerts
|

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
81
0

Year Published

2003
2003
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 123 publications
(87 citation statements)
references
References 12 publications
6
81
0
Order By: Relevance
“…Both TIQ and MPP + are reported to cause apoptosis in PC12 cells (7,8) and dopaminergic neurons (2,6,8,27). However, several investigators suggest that MPP + elicits nonapoptotic cell death in PC12 cells (11,28).…”
Section: Discussionmentioning
confidence: 99%
“…Both TIQ and MPP + are reported to cause apoptosis in PC12 cells (7,8) and dopaminergic neurons (2,6,8,27). However, several investigators suggest that MPP + elicits nonapoptotic cell death in PC12 cells (11,28).…”
Section: Discussionmentioning
confidence: 99%
“…Rasagiline prevents apoptosis via multiple intracellular processes including the induction of survival genes and the suppression of proapoptotic genes (483,825,869). In addition, rasagiline can mediate direct PTP inhibition, as demonstrated in cellula and in isolated mitochondria (8). Whether this effect is truly responsible for the neuroprotective effect of rasagiline, however, remains to be proven.…”
Section: Inhibitors Of the Permeability Transition Porementioning
confidence: 99%
“…Also, pre-administration of the drug was shown to protect against MPTP- [125] and 6-OHDA-induced [126] opening of the mPTP, rupture of the mitochondrial outer membrane and a decline in mitochondrial membrane potential. In this regard, rasagiline was seen to bind directly to the mPTP, thereby stabilizing mitochondrial membrane potential [129].…”
Section: Reviewmentioning
confidence: 96%
“…The observation that the neuroprotective benefits of rasagiline are only observed at concentrations below the MAO inhibition threshold in preclinical animal models, while the same was reported in cellular systems not containing MAO-B [128,129], suggests that the neuroprotection provided by the drug is not entirely attributable to MAO-B inhibition and that multiple mechanisms, in particular mitochondria-based, may be involved. This includes rasagiline-induced increased expression of the anti-apoptotic proteins Bcl-2 and BclxL and downregulating the expression of Bax and Bad, the gateway proteins to the mitochondrial pathway of apoptosis [130,131].…”
Section: Reviewmentioning
confidence: 99%